Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized,placebo-controlled trial

Abstract

We present the design of a double-blind, randomised placebo-controlled phase III study to evaluate safety and efficacy of IVIG in the treatment of patients suffering from primary or secondary chronic progressive multiple sclerosis. The primary endpoint is disability. Two measures of disability were chosen in order to assess the primary end point: (a) sustained improvement (assessed at month 6, confirmed at month 9) and (b) progression to increasing disability of the disease (sustained for 3 months) at any time during the course of this 2 years study. The disability is measured by the Extended Disability Status Scale (EDSS). Secondary end points include the assessment of visual function, functions of the upper extremity, cognitive functions, depression and quality of life.

Keywords

chronic progressive multiple sclerosis intravenous immunoglobulin disability clinical trial

Get full access to this article

View all access options for this article.

References

Wekerle H. et al. (1994). Animal Models. Ann Neurol 36: 47-53.

Achiron A. et al. (1994) Intravenous gamma globulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of age and mode of action. JNNP 57: 57-61.

Poehlau et al. (1996) Wirkmechanismen intravenöser Immunglobuline. Fortschritte der Medizin 31: 42-48.

Achiron A. et al. (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting Multiple sclerosis. Arch Neurol 49: 1233-1236.

Maida E. (1992) Zusammenfassendes Gutachten über Multiple Sklerose Daten Dr Eva Maida. Diplom Ing. Dr Neumann und Team.

Rothfelder U. , Neu I. , Pelka R. (1982) Therapie der MS mit Immunglobulin G. Miinch Med Wochenschr 124/4: 74-78.

Schuller E. , Goevaerts A. (1983) First Results of Immunotherapy with Immunoglobulin G in Multiple Sclerosis Patients. Eur Neurol 22: 205 - 212.

Soukop W. , Tschabitscher H. (1984) Therapeutischer Einsatz von Immunglobulinen bei der MS. Neurologica et psychiatrica (Number?): 54 - 57.

Soukop W. , Tschabitscher H. (1986) Gammaglobulintherapie bei Multipler Sklerose. WMW 18: 477-480.

10.

Yan J. , Richert J. , Sirdowsky M. (1990) High dose intravenous immunoglobulin for multiple sclerosis. Lancet 336: 692 (Letter).

11.

Van Engelen Bgm et al. (1992) Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 32: 384 - 385.

12.

Rodriguez M. , Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27: 12 -17.

13.

Shakib F. , Stanworth DR (1990) Human IgG Subclasses in health and disease. Part I. La Ricerca Clin Lab 10: 463- 479.

14.

Dixon WJ , Kuzma JW (1974) Data reduction in large clinical trials. Commmunity Stat 3: 301-324.

15.

McHorney CA , Ware JE , Raczek A. (1993) The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 31: 247-263.

16.

Rudick R. et al. (1996) Clinical Outcomes Assessment in Multiple Sclerosis. Ann Neurol 40: 469-479.

17.

Kurtzke JF (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580-583.

18.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444-1452.

19.

Whitaker JN , McFarland HF , Rudge P. , Reingold SC (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analyses . Mulitple Sclerosis 1: 37-47.

20.

Goodkin DE , Hertzgaard D. , Seminary J. (1988) Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole-peg-tests . Arch Phys Med Rehabil 69: 850-854.

21.

Andresen EM , Malmgren JA , Carter W. , Patrick DI (1994) Screening for Depression in well older adults: Evaluation of a short form of the CES-D. Am J Prev Med 10: 77 - 84.

22.

Poehlau D. , Amoiridis G. , Postert T. et al. (1995) Intravenous Immunoglobulin (IVIG) for the treatment of progressive multiple sclerosis (MS). J Neuroimmunmol (suppl.) 1: 47.

23.

Syndulko K. et al. (1993) Neuroperformance evaluation of multiple sclerosis disease progression in a clinical trial: implications for neurological outcomes. J Neural Rehabil 7: 153-176.